Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

EAB GROUP PLC: ACQUISITION OF OWN SHARES 27.07.2020

EAB GROUP PLC NOTIFICATION 27.07.2020 at 18:30 EAB GROUP PLC: ACQUISITION OF OWN SHARES 27.07.2020 Date 27.07.2020Exchange transaction BuyShare class EABAmount 160Average price/share 2.3000 EURHighest price/share 2.3000 EURLowest price/share 2.3000 EURTotal price 368.00 EUR The shares held by EAB Group Plc on 27.07.2020: EAB 30,167 On behalf of EAB Group Plc  Skandinaviska Enskilda Banken AB (Publ) Antti Salakka         Mikko Virtanen For more information, please

ShaMaran Atrush June Oil Sales Payment Received

Vancouver, BC, July 27, 2020 /CNW/ - ShaMaran Petroleum Corp. ("ShaMaran" or the "Company") (SNM - TSXV, Nasdaq First North Growth Market) provides the following update to stakeholders.  The Company confirms that a payment of $12.5 million ($4.5 million net to the Company) has been received from the Kurdistan Regional Government for Atrush crude oil sales during June 2020.   OTHER This information is information that ShaMaran Petroleum Corp is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the

Kongsberg Automotive ASA – Final results of subsequent offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, HONG KONG, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO BUY, SELL OR SUBSCRIBE FOR ANY SECURITIES DESCRIBED HEREIN. Reference is made to the announcement by Kongsberg Automotive ASA (the "Company") on 24 July 2020 regarding the preliminary results of the subsequent offering in the Company with gross proceeds of NOK 300 million by issuance of 3,000,

#20-259 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details see attached file. For further information concerning this NGM notice please contact: Listing on +46 8 566 390 20 or at listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for

Scanning timber inventory with NAUTIZ X2

Timber merchants are using the Nautiz X2  rugged handheld with long-range pistol grip scanner to track forest inventory throughout New Zealand and Australia. Thanks to the ultra-rugged design and 4G cellular connectivity of the Nautiz X2, plus long-distance barcode reading capabilities of the pistol grip, this unique solution allows users to scan and transmit massive amounts of data in outdoor timber yards, even if no WiFi connection is available. Max Birt Sawmills (MBS) stocks about 6,000 unique

SpectrumOne’s rights issue of free-of-payment units is oversubscribed

On Wednesday, the 22[nd] of July 2020, SpectrumOne AB’s (“SpectrumOne” or the “Company”) rights issue of free-of-payment units, consisting of a total of 45 261 240 warrants of two series (TO 2 and TO 3) ended. The rights issue was oversubscribed and approximately 91.63 percent of the rights issue was subscribed for by exercise of unit rights (subscription rights for units allotted to shareholders). A total of 22 630 620 units were issued through the rights issue consisting of 22 630 620 warrants of series TO 2 and 22 630 620 warrants of series TO 3. The allocation of units has been made

Asetek A/S Announces Transactions Carried Out Under the Current Share Buyback Programme in Accordance With the "Safe Harbour Method"

July 27, 2020 - On May 19, 2020, Asetek A/S launched a share buyback programme, as described in company announcement of May 19, 2020. According to the programme, Asetek A/S will in the period until September 30, 2020 buy back own shares up to a maximum value of USD 4.5 million and with a maximum of 1,038,082 shares. The share buyback programme will be implemented in accordance with Regulation (EU) no. 596/2014 of 16th April 2014 of the European Parliament and Council and Commission Delegated Regulation (EU) no. 2016/1052, also referred to as the Safe Harbour rules. Trading day

Notification in accordance with the Finnish Securities Market Act Chapter 9 § 5: BlackRock, Inc.’s holding in Wärtsilä Corporation

Wärtsilä Corporation, Stock exchange release, 27 July 2020 at 3:00 pm EESTNotification in accordance with the Finnish Securities Market Act Chapter 9 § 5: BlackRock, Inc.’s holding in Wärtsilä CorporationBlackRock, Inc. has informed Wärtsilä Corporation that it has crossed above the 5% disclosure limit on shares and voting rights on 24 July 2020. Total position of BlackRock, Inc. and its funds subject to the notification: % of % of shares Total of Total number of shares shares and voting both in % and voting rights of

Hilti and Ottobock Bring Exoskeleton Solutions to the Construction Industry

July 27, 2020 – The Hilti Group has entered into a technology partnership with Ottobock SE & Co. KGaA to develop exoskeletal systems. Such solutions open new possibilities in terms of health protection and productivity and represent a future market in the construction industry.The construction technology group Hilti and the medical technology company Ottobock are combining their know-how in the fields of safety, health protection and biomechanics to expand their portfolio of ergonomic solutions. Both companies have decades of experience in their respective fields and will cooperate in the

Glaston publishes the January 1– June 30, 2020 Interim Report on Thursday, August 6, 2020 at 13.00

Glaston Corporation     Press release        27.7.2020 at 12.40Glaston Corporation will publish its January–June 2020 Interim Report on Thursday, August 6, 2020 at around 13.00 p.m. Finnish time. The Interim Report and presentation will be available as soon as possible after publishing on the Company’s internet pages at www.glaston.net.  Glaston’s Acting CEO Sasu Koivumäki and CFO Päivi Lindqvist will present the financial result to analysts, investors and media representatives on the publication day at 15.00 (Finnish time) in Finnish at Glaston’s premises on Lönnrotinkatu 11, Helsinki.

LocalizeDirect raises $1.1 million for Gridly - a headless CMS tailor-made for game developers

Gridly is the response to industry requirements as it shifts to games as a service modelSweden-based localization and software company LocalizeDirect  announces an investment of SEK10,264,530 (USD1,130,802) from Entreprenörinvest, owned by The IKEA Family Foundation and a number of Swedish venture capital firms and private individuals, including Innovum Invest. Former investors also participated in the financing round. Jan Andersson, a founder and former CEO of ReadSoft (now Kofax), will join

KebNi releases Q2 2020 Report

KebNi AB (former Advanced Stabilized Technologies Group AB) reports Revenue of 18.8 MSEK and an EBITDA of 0.9 MSEK for Q2, 2020. This is the 4[th] quarter in a row with a positive EBITDA and the highest Revenue in one quarter to date. Q2 highlights are change of name from ASTG AB to KebNi AB, announcement of SAAB Dynamics development program for IMU, Satmission acquisition in SatCom, application for listing on Nasdaq First North from end of August 2020, and the strengthening of sales efforts in India and North America. Outlook indicates increased sales activity and continuation of the growth

SimCorp A/S – Share buyback program

Company Announcement no. 35/2020 On February 5, 2020 SimCorp A/S announced a share buyback program in compliance with the provisions of Regulation No. 596/2014 of the European Parliament and of the Council on market abuse (the Market Abuse Regulation - MAR) and delegated legislation under MAR. In connection with the program SimCorp A/S will repurchase shares for an amount of up to EUR 10.0m, to be executed during the period from February 5, 2020 to July 31, 2020. The following transactions have been executed under the program:          Date Number of shares

Metsä Board paperboards hold industrial compostability certifications

Metsä Board Corporation press release 27.07.2020Metsä Board, a leading European producer of premium lightweight paperboards and part of Metsä Group, is glad to announce that its paperboards have now achieved DIN CERTCO certificates in industrial compostability complying with DIN EN 13432 and ASTM D6400 standards. In addition, Metsä Board’s eco-barrier paperboard MetsäBoard Prime FBB EB also holds a home compostability certificate. As one of the leading companies, Metsä Board provides certification across its product line helping customers choose packaging materials that comply with their

Valmet Oyj – Manager’s transaction: Karlstedt, Bertel

Valmet Oyj July 27, 2020 at 11:00 a.m. EET Valmet Oyj - Managers' Transactions____________________________________________ Person subject to the notification requirementName: Karlstedt BertelPosition: Other senior manager(X) Legal personIssuer: Valmet OyjLEI: 213800D9O7FUQDH83V62 Notification type: INITIAL NOTIFICATIONReference number: 213800D9O7FUQDH83V62_20200724130612_2____________________________________________ Transaction date: 2020-07-24Venue: OFF-EXCHANGE TRANSACTIONS (XOFF)Instrument type: SHAREISIN: FI4000074984Nature of the transaction:

Leading Edge Materials Announces C$3,520,000 Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER, OR A SOLICITATION OF ANY OFFER, TO BUY OR SUBSCRIBE FOR ANY SECURITIES IN LEADING EDGE MATERIALS IN ANY JURISDICTION.Vancouver, July 27, 2020 – Leading Edge Materials Corp. (“Leading Edge Materials” or the “Company”) (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) announces

Synact Pharma announces outcome in the exercise of warrants, will receive approximately MSEK 32.4

On Wednesday, July 22, 2020, the exercise period for SynAct Pharma AB's (“SynAct” or “the Company”) warrants of series TO 2 (“TO 2”) ended. A total of 4,839,860 warrants of series TO 2 were exercised, corresponding to a subscription rate of approximately 98.95 percent of TO 2. SynAct is thus provided with a total of approximately MSEK 32.4 before issue costs. With the issue proceeds, the Company has secured the capital needed to finance several important milestones, such as demonstrating Proof-of-Concept for phase II studies with AP1189 within RA and NS.CEO Jeppe Øvlesen comments: “I

Scout Gaming launches 1 Million Euro Fantasy Premier League Season Game

As the leading B2B fantasy sports provider, Scout Gaming Group is following up last year’s “quarter of a mill” Premier League Season Game by offering €1,000,000 guaranteed prize pool for this season. With 50,000 available seats at €25 each, the competition promises to pay out 1,250 prizes, with the 1st place securing €200,000. The tournament will be available for Scout Gaming’s clients in the world-wide network.Scout Gaming’s seasonal game has similarities to the popular official Fantasy Premier League game with regards to budget, number of players, and some of the scoring rules. There are

alquence recommended for approval in the EU by CHMP for chronic lymphocytic leukaemia

27 July 2020 07:10 BST Calquence recommended for approval in theEU by CHMP for chronic lymphocytic leukaemia Recommendation based on two Phase III trials demonstrating superior progression-free survival across multiple settings while maintaining favourable tolerability AstraZeneca's Calquence (acalabrutinib) has been recommended for marketing authorisation in the European Union (EU) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in adults.[1] The Committee for Medicinal Products for Human Use (CHMP) of the

Press Release: Awarded grant to develop a novel electrolyser stack to enable lower cost hydrogen generation

(Oslo, 27 July, 2020) Proton Energy Systems, Inc. (dba “Nel Hydrogen US”), a wholly owned subsidiary of Nel ASA (Nel, OSE:NEL), has been awarded a $4.4 million grant by the Department of Energy (DOE) for development of advanced components and manufacturing methods to enable low cost hydrogen from electrolysis. The purpose of the project is to leverage the DOE National Lab capabilities to develop advanced cell configurations which optimize interactions between components such as flow and conductivity, and translate those configurations to low cost manufacturing methods in collaboration

Vicore Pharma doses first COVID-19 patient in the ATTRACT study in India

Gothenburg, July 27, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces that the first patient in the ATTRACT study has been dosed in India at Ruby Hall Clinic in Pune.Ruby Hall Clinic, Pune, has dosed the first patient, two more sites are fully approved and are also expected to start enrollment this week and five more sites are being initiated. “With 40,000 new cases per day and still increasing, the prerequisites for a COVID-19 trial are dramatically different in India versus the UK”, says

Imfinzi recommended for approval in the EU by CHMP for extensive-stage small cell lung cancer

27 July 2020 07:05 BST Imfinzi recommended for approval in the EU byCHMP for extensive-stage small cell lung cancer Only PD-1/PD-L1 immunotherapy to demonstrate a significant survival benefit and improved response rate in combination with a choice of chemotherapies AstraZeneca's Imfinzi (durvalumab) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin. SCLC is a highly

AstraZeneca and Daiichi Sankyo enter collaboration to develop and commercialise new antibody drug conjugate

This announcement contains inside information 27 July 2020 07:00 BST AstraZeneca and Daiichi Sankyo enter collaboration todevelop and commercialise new antibody drug conjugate Potential new medicine DS-1062 could redefine treatmentstandards in lung, breast and multiple other cancers AstraZeneca has entered into a new global development and commercialisation agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) for DS-1062, Daiichi Sankyo's proprietary trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) and potential new medicine for

There are no items matching the current filter
There are no more items matching the current filter
Back to top